Antibe Therapeutics Inc.

Quick facts

Phase 2 pipeline

• ATB-346 low dose · Pain
  ATB-346 low dose is a nonsteroidal anti-inflammatory drug (NSAID) that selectively targets COX-2 to reduce gastrointestinal toxicity.
• ATB-346 mid-dose · Pain
  ATB-346 mid-dose is a nonsteroidal anti-inflammatory drug (NSAID) that selectively targets COX-2 to reduce gastrointestinal toxicity.
• ATB-346 standard dose · Pain
  ATB-346 is a nonsteroidal anti-inflammatory drug (NSAID) that selectively targets COX-2 to reduce gastrointestinal toxicity.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Antibe Therapeutics Inc. portfolio CI brief
• Antibe Therapeutics Inc. pipeline updates RSS

Related

• Sector hub: All tracked pharma companies